SCHEMBL5558468

SCHEMBL5558468

CC(C)CC(CC(=O)NO)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(N)=O

nearest known ligand 0.82

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 13/20 0.82
MMP8 P22894 12/20 0.82
MMP9 P14780 11/20 0.82
MMP1 P03956 10/20 0.82
MMP7 P09237 2/20 0.82
ADAM10 O14672 1/20 0.82
ADAM12 O43184 1/20 0.82
ADAMTS4 O75173 1/20 0.82
MMP3 P08254 1/20 0.82
MMP12 P39900 1/20 0.82
MMP13 P45452 1/20 0.82
MMP14 P50281 1/20 0.82
MMP15 P51511 1/20 0.82
MMP16 P51512 1/20 0.82
ADAM17 P78536 1/20 0.82
ADAM9 Q13443 1/20 0.82
MMP26 Q9NRE1 1/20 0.82
MMP17 Q9ULZ9 1/20 0.82
ADAMTS5 Q9UNA0 1/20 0.82

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ilomastat SCHEMBL7870487 0.90 MMP2 (1.00) MMP2MMP8MMP9MMP1MMP7
Ilomastat SCHEMBL29412562 0.90 MMP2 (1.00) MMP2MMP8MMP9MMP1MMP7
Ilomastat SCHEMBL6691646 0.90 MMP2 (1.00) MMP2MMP8MMP9MMP1MMP7
Ilomastat SCHEMBL13575799 0.90 MMP2 (1.00) MMP2MMP8MMP9MMP1MMP7
Ilomastat SCHEMBL8190117 0.90 MMP2 (1.00) MMP2MMP8MMP9MMP1MMP7
Ilomastat SCHEMBL4394885 0.90 MMP2 (1.00) MMP2MMP8MMP9MMP1MMP7
Ilomastat SCHEMBL4293696 0.90 MMP2 (1.00) MMP2MMP8MMP9MMP1MMP7
Ilomastat SCHEMBL35303 0.90 MMP2 (1.00) MMP2MMP8MMP9MMP1MMP7
SCHEMBL4845965 0.89 MMP2 (0.84) MMP2MMP8MMP9MMP1MMP7
SCHEMBL5060570 0.89 MMP2 (0.83) MMP2MMP8MMP9MMP1MMP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070197577-A1 Inhibitors of anthrax lethal factor CENGENT THERAPEUTICS (US) 2007-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197577-A1 Inhibitors of anthrax lethal factor APAF1, ANTXR2, LITAF MMP2 85/4885MMP8 24/4885MMP9 182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.